The BioPharm Brief: Weekly Insulin, Excipient Data, and the Fate of a Lung Cancer ADC

Sep 28, 08:32 PM
Headliner
Share
Subscribe

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, regulatory progress, and drug development. Today’s update covers a new once-weekly insulin option for type 2 diabetes, efforts to standardize excipient information sharing, and a regulatory setback for an antibody-drug conjugate in small cell lung cancer.

Share
Subscribe
Next
The BioPharm Brief: Deals, Data, and a $2 Billion Bet
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief